pI: 6.016 |
Length (AA): 740 |
MW (Da): 83219 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_142175)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.34.0510 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_350480.1 | Protein kinase domain containing protein, putative |
Leishmania infantum | LinJ.35.0480 | hypothetical protein, conserved |
Leishmania major | LmjF.35.0490 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.34.0490 | hypothetical protein, conserved |
Trypanosoma brucei gambiense | Tbg972.10.4850 | protein kinase, putative |
Trypanosoma brucei | Tb927.10.3900 | CAMK/CAMKL family protein kinase, putative |
Trypanosoma congolense | TcIL3000_10_3230 | protein kinase, putative |
Trypanosoma cruzi | TcCLB.503635.10 | CAMK/CAMKL family protein kinase, putative |
Trypanosoma cruzi | TcCLB.511001.60 | CAMK/CAMKL family protein kinase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.3900 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.3900 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.3900 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.10.3900 this record | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Plasmodium falciparum (isolate 3D7) | Calcium-dependent protein kinase 4 | 528 aa | 26.7% | 524 aa | Compounds | References |
Bos taurus | Glycogen synthase kinase-3 beta splice variant X1 | 419 aa | 26.1% | 345 aa | Compounds | References |
Sus scrofa | Glycogen synthase kinase 3 beta | 420 aa | 26.1% | 345 aa | Compounds | References |
Xenopus laevis | Aurora kinase B-A | 361 aa | 26.8% | 299 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 25.6% | 309 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 25.9% | 301 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 27.6% | 290 aa | Compounds | References |
Rattus norvegicus | Glycogen synthase kinase-3 beta | 420 aa | 26.1% | 345 aa | Compounds | References |
Sus scrofa | Casein kinase I isoform alpha | 125 aa | 29.9% | 117 aa | Compounds | References |
Bos taurus | Calmodulin | 149 aa | 20.8% | 173 aa | Compounds | References |
1 literature reference was collected for this gene.